Hubbry Logo
Digoxin toxicityDigoxin toxicityMain
Open search
Digoxin toxicity
Community hub
Digoxin toxicity
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Digoxin toxicity
Digoxin toxicity
Digoxin toxicity
View on Wikipedia
from Wikipedia
Digoxin toxicity
Other namesDigoxin poisoning, digoxin overdose
Drawings of Digitalis purpurea
SpecialtyEmergency medicine
Symptomsvomiting, loss of appetite, confusion, blurred vision, changes in color perception, decreased energy[1]
ComplicationsHeart dysrhythmia[1]
CausesExcessive digoxin, plants such as foxglove[1][2]
Risk factorsLow potassium, low magnesium, high calcium[1]
Differential diagnosisAcute coronary syndrome, hyperkalemia, hypothyroidism, beta blocker toxicity[2]
TreatmentSupportive care, activated charcoal, atropine, digoxin-specific antibody fragments[2][1]
Frequency~2,500 cases per year (US)[2]

Digoxin toxicity, also known as digoxin poisoning, is a type of poisoning that occurs in people who take too much of the medication digoxin or eat plants such as foxglove that contain a similar substance.[1][2] Symptoms are typically vague.[1] They may include vomiting, loss of appetite, confusion, blurred vision, changes in color perception, and decreased energy.[1] Potential complications include an irregular heartbeat, which can be either too fast or too slow.[1]

Toxicity may occur over a short period of time following an overdose or gradually during long-term treatment.[1] Risk factors include low potassium, low magnesium, and high calcium.[1] Digoxin is a medication used for heart failure or atrial fibrillation.[3] An electrocardiogram is a routine part of diagnosis.[2] Blood levels are only useful more than six hours following the last dose.[1]

Activated charcoal may be used if it can be given within two hours of the person taking the medication.[1] Atropine may be used if the heart rate is slow while magnesium sulfate may be used in those with premature ventricular contractions.[2] Treatment of severe toxicity is with digoxin-specific antibody fragments.[1] Its use is recommended in those who have a serious dysrhythmia, are in cardiac arrest, or have a potassium of greater than 5 mmol/L.[1] Low blood potassium or magnesium should also be corrected.[1] Toxicity may reoccur within a few days after treatment.[1]

In Australia in 2012 there were about 140 documented cases.[1] This is a decrease by half since 1994 as a result of decreased usage of digoxin.[1] In the United States 2500 cases were reported in 2011 which resulted in 27 deaths.[2] The condition was first described in 1785 by William Withering.[4]

Signs and symptoms

[edit]

Digoxin toxicity is often divided into acute or chronic toxicity. In both of these toxicity, cardiac effects are of the greatest concern. With an acute ingestion, symptoms such as nausea, vertigo, and vomiting are prominent. On the other hand, nonspecific symptoms are predominant in chronic toxicity. These symptoms include fatigue, malaise, and visual disturbances.[5]

The classic features of digoxin toxicity are nausea, vomiting, abdominal pain, headache, dizziness, confusion, delirium, vision disturbance (blurred or yellow vision). It is also associated with cardiac disturbances including irregular heartbeat, ventricular tachycardia, ventricular fibrillation, sinoatrial block and AV block.[6]

Diagnosis

[edit]

In individuals with suspected digoxin toxicity, a serum digoxin concentration, serum potassium concentration, creatinine, BUN, and serial electrocardiograms is obtained.[7]

ECG

[edit]
An ECG showing digoxin toxicity with the classic "scooped out" ST segment

In digoxin toxicity, the finding of frequent premature ventricular beats (PVCs) is the most common and the earliest dysrhythmia. Sinus bradycardia is also very common. In addition, depressed conduction is a predominant feature of digoxin toxicity. Other ECG changes that suggest digoxin toxicity include bigeminal and trigeminal rhythms, ventricular bigeminy, and bidirectional ventricular tachycardia.[5]

Blood test

[edit]

The level of digoxin for treatment is typically 0.5-2 ng/mL.[8] Since this is a narrow therapeutic index, digoxin overdose can happen. A serum digoxin concentration of 0.5-0.9 ng/mL among those with heart failure is associated with reduced heart failure deaths and hospitalizations.[9] It is therefore recommended that digoxin concentration be maintained in approximately this range if it is used in heart failure patients.

High amounts of the electrolyte potassium (K+) in the blood (hyperkalemia) is characteristic of digoxin toxicity.[6] Digoxin toxicity increases in individuals who have kidney impairment. This is most often seen in elderly or those with chronic kidney disease or end-stage kidney disease.[10]

Treatment

[edit]
Digoxin immune Fab used to treat digoxin toxicity

The primary treatment of digoxin toxicity is digoxin immune fab, which is an antibody made up of anti-digoxin immunoglobulin fragments. This antidote has been shown to be highly effective in treating life-threatening signs of digoxin toxicity such as hyperkalemia, hemodynamic instability, and arrhythmias.[11] Fab dose can be determined by two different methods. First method is based on the amount of digoxin ingested whereas the second method is based on the serum digoxin concentration and the weight of the person.[10]

Other treatment that may be used to treat life-threatening arrhythmias until Fab is acquired are magnesium, phenytoin, and lidocaine. Magnesium suppresses digoxin-induced ventricular arrhythmias while phenytoin and lidocaine suppresses digoxin-induced ventricular automaticity and delay afterdepolarizations without depressing AV conduction. In the case of an abnormally slow heart rate (bradyarrhythmias), Atropine, catecholamines (isoprenaline or salbutamol), and/or temporary cardiac pacing can be used.[8]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Digoxin toxicity

View on Grokipedia
from Grokipedia
Digoxin toxicity, a specific form of digitalis poisoning, is a potentially life-threatening condition arising from excessive levels of digoxin, a cardiac glycoside derived from the foxglove plant (Digitalis lanata) and used primarily to manage heart failure and rate control in atrial fibrillation. With a narrow therapeutic index of 0.8–2.0 ng/mL, toxicity often occurs when serum concentrations exceed 2.4 ng/mL, though symptoms can manifest even within therapeutic ranges due to factors like electrolyte imbalances. It presents with a spectrum of gastrointestinal, neurological, visual, and cardiac manifestations, including nausea, confusion, yellow-tinted vision, and arrhythmias that can lead to hemodynamic instability or sudden death. The causes of digoxin toxicity are multifaceted, encompassing acute overdose in individuals without prior exposure, chronic accumulation from reduced renal clearance (e.g., in elderly patients or those with impairment), and acute-on-chronic scenarios where an additional dose exacerbates ongoing therapy. Risk factors include electrolyte disturbances such as , hypomagnesemia, or hypercalcemia, which potentiate digoxin's effects on the sodium-potassium pump, as well as interactions with agents like , verapamil, or quinidine that inhibit digoxin clearance. , , and advanced age further increase susceptibility, which contributed to approximately 5,000 to 8,000 visits annually in the United States during 2005–2010, though incidence has continued to decline since the 1990s with reduced digoxin prescriptions. Clinically, digoxin toxicity manifests early with nonspecific symptoms like anorexia, , , and , progressing to characteristic visual aberrations such as (yellow-green halos around lights) and neurological effects including or seizures in severe cases. Cardiac involvement is the most critical, featuring ECG changes like scooped ST depressions, prolonged PR intervals, and arrhythmias ranging from and atrioventricular blocks to bidirectional or , with in-hospital mortality rates of approximately 4% to 13% in cases of suspected . Diagnosis relies on clinical suspicion, serum digoxin levels (measured at least 6 hours post-dose), serum , and ECG findings, as levels alone do not always correlate with severity. Management prioritizes supportive care, including gastrointestinal decontamination with activated charcoal for recent acute ingestions, correction of electrolytes (e.g., supplementation if <4 mmol/L), and monitoring in a cardiac setting. For life-threatening features such as hemodynamically unstable arrhythmias, hyperkalemia (>5.0–6.5 mmol/L), or , the digoxin immune Fab (DigiFab) is administered intravenously, with dosing calculated based on serum levels or estimated ingestion (e.g., 10 vials for unstable adults); it binds free digoxin, neutralizing effects within 20–90 minutes and reducing mortality significantly. Temporary pacing or antiarrhythmics like lidocaine may be used adjunctively, but digoxin therapy should be withheld and restarted cautiously after clearance, particularly in renal impairment where the drug's can extend to a week.

Introduction and Background

Overview of Digoxin

Digoxin is a cardiac glycoside derived from the leaves of the foxglove plant, Digitalis lanata. First isolated in 1930 by Sydney Smith, it builds on the historical use of digitalis extracts in cardiovascular medicine dating back to the 18th century, with purified digoxin gaining widespread adoption from the 1960s following its FDA approval in 1954. Its clinical application has since declined due to the rise of newer agents, such as beta-blockers, which offer superior mortality benefits in heart failure management. Digoxin is primarily indicated for treating heart failure, where it improves cardiac output, and for rate control in atrial fibrillation. The drug's mechanism of action centers on inhibition of the Na⁺/K⁺-ATPase pump in cardiac myocytes, which elevates intracellular sodium levels and indirectly increases calcium availability via reduced sodium-calcium exchanger activity, thereby enhancing through a positive inotropic effect. It also augments parasympathetic , producing a negative effect that slows . Therapeutic dosing typically involves of 0.125 to 0.25 mg daily in adults, targeting serum concentrations of 0.5 to 2.0 ng/mL; for , recent guidelines recommend 0.5 to 1.0 ng/mL to optimize benefits and reduce toxicity risk. Pharmacokinetically, exhibits 60-80% , with primary elimination via the kidneys—50-70% excreted unchanged in —and minimal hepatic accounting for the remainder. In patients with normal renal function, its is 36-48 hours, enabling steady-state levels after 5-7 days of consistent dosing. This narrow underscores the need for precise monitoring to prevent toxicity.

Pathophysiology of Toxicity

Digoxin's therapeutic effects arise from partial inhibition of the Na+/K+-ATPase pump in cardiac myocytes, which increases intracellular sodium and, via the sodium-calcium exchanger, elevates intracellular calcium to enhance contractility; however, in toxicity, this inhibition is exaggerated, leading to excessive intracellular sodium and calcium accumulation. This overload promotes spontaneous calcium release from the sarcoplasmic reticulum, causing delayed afterdepolarizations that trigger arrhythmias, such as bidirectional ventricular tachycardia. The Na+/K+-ATPase normally maintains a potassium gradient with intracellular concentrations approximately 30- to 40-fold higher than extracellular levels, but digoxin's inhibition disrupts this equilibrium, impairing potassium influx and contributing to electrophysiological instability. In acute digoxin overdose, profound Na+/K+-ATPase inhibition prevents cellular uptake, resulting in extracellular efflux and severe , which further exacerbates cardiac toxicity by altering membrane potentials. In contrast, often presents with normal serum levels despite intracellular depletion, as ongoing mild inhibition and concomitant factors like use lead to total body loss without acute extracellular shifts. Additionally, enhances by sensitizing autonomic ganglia and , causing parasympathetic overstimulation that depresses automaticity and conduction, thereby promoting bradyarrhythmias such as . Central nervous system effects in digoxin toxicity stem from direct inhibition of neuronal Na+/K+-ATPase, leading to through disrupted neuronal signaling and imbalances. Visual disturbances, including halos around lights, arise from retinal cell disruption due to similar pump inhibition in photoreceptor cells, altering visual processing. Gastrointestinal manifestations result from both vagal overstimulation, which increases gastric secretions and motility, and direct Na+/K+-ATPase inhibition in mucosal cells, causing irritation and or .

Causes and Risk Factors

Etiology

Digoxin toxicity arises primarily from two main exposure patterns: and chronic. typically results from a large single dose, such as intentional overdose in attempts or accidental massive ingestion exceeding 10 mg in adults, or iatrogenic administration via rapid intravenous loading without prior tolerance. These events lead to rapid elevation of serum levels, often without baseline exposure, and account for a minority of cases, with intentional overdoses comprising a substantial portion of acute presentations in reported series. In contrast, develops gradually from accumulation during therapeutic dosing, particularly in patients with renal impairment that prolongs , with an estimated incidence of 0.8% to 4% among those on long-term therapy. This form predominates in clinical practice, representing over 95% of cases in some analyses. Drug interactions frequently precipitate toxicity by reducing digoxin clearance or enhancing its effects. Inhibitors of P-glycoprotein, such as verapamil and , can increase serum digoxin levels by 50% to 75% and nearly double them, respectively, through diminished renal and non-renal excretion. Endogenous factors like , defined as serum below 3.5 mEq/L, potentiate digoxin binding to Na+/K+-ATPase, thereby increasing the risk of toxicity and associated arrhythmias. This interaction heightens cardiac sensitivity to digoxin, often in the context of concurrent use. A 2014 analysis estimated that digoxin toxicity accounted for 3.3% of visits and 5.9% of hospitalizations among cardiovascular adverse drug events, underscoring its clinical burden despite declining use. Renal impairment, as a key predisposing element, is briefly noted here as it facilitates accumulation in chronic scenarios.

Predisposing Factors

Renal dysfunction is a primary predisposing factor for toxicity, as is predominantly eliminated by the kidneys via glomerular filtration and tubular secretion. In patients with (CKD) and estimated (GFR) less than 60 mL/min/1.73 m², clearance is significantly reduced, prolonging the elimination from the normal 36-48 hours to over 100 hours in moderate to severe impairment, thereby increasing the risk of accumulation and toxicity. Dose adjustments are recommended for maintenance therapy when GFR falls below 50 mL/min/1.73 m² to prevent supratherapeutic levels. Electrolyte imbalances further heighten susceptibility by altering digoxin's pharmacodynamic effects on the Na⁺/K⁺-ATPase pump. increases digoxin's binding affinity to the pump, potentiating its inhibitory effects and toxicity at lower serum concentrations; hypomagnesemia exacerbates this by impairing repletion and directly sensitizing cardiac tissue; while hypercalcemia enhances in synergy with , raising the risk of arrhythmias. Demographic factors play a significant role, with elderly patients over 65 years being particularly vulnerable due to age-related declines in renal function, reduced (which decreases digoxin's ), and frequent . In , the risk is elevated primarily from accidental ingestion, as children may access medications unsupervised, leading to acute exposures disproportionate to their body weight. Certain comorbidities amplify toxicity risk through pharmacokinetic and pharmacodynamic alterations. reduces metabolism and renal excretion while shrinking its , resulting in higher serum levels; patients exhibit increased myocardial sensitivity to due to downregulated Na⁺/K⁺-ATPase and altered distribution, even at therapeutic doses. Lifestyle factors such as or adherence to a low-sodium diet can mimic , contracting the volume of distribution and concentrating in plasma, while also impairing renal perfusion and clearance. Drug interactions, often from , can additionally precipitate toxicity by inhibiting clearance or enhancing its effects.

Clinical Manifestations

Non-Cardiac Symptoms

Non-cardiac manifestations of digoxin toxicity primarily involve the gastrointestinal, neurological, and visual systems, often presenting as early indicators before cardiac involvement. Gastrointestinal symptoms are among the most frequent initial signs, particularly in , where they can precede cardiac effects in a majority of cases. Anorexia is particularly common, affecting 30% to 70% of overdosed patients, alongside , , , and . These symptoms arise from direct stimulation of the in the and vagal effects on the gut. Neurological features include fatigue, confusion, , , and , which are nonspecific and may mimic other conditions such as or . In severe acute overdose, these can progress to seizures or due to . Visual disturbances, occurring in approximately 10% to 25% of toxicity cases, are relatively specific and include —characterized by yellow-green halos around lights—, and . This results from inhibition of sodium-potassium in retinal photoreceptors, leading to altered color perception. In , additional systemic effects may include from prolonged anorexia. Overall, these symptoms are often vague and insidious, underscoring the need for clinical suspicion in at-risk patients.

Cardiac Manifestations

Cardiac manifestations of digoxin toxicity primarily involve disturbances in cardiac rhythm and conduction, which can range from benign to life-threatening arrhythmias. These effects arise from digoxin's inhibition of the pump, leading to increased intracellular calcium and enhanced , as well as parasympathetic stimulation that slows conduction. Bradyarrhythmias are common and result from heightened , manifesting as , atrioventricular (AV) blocks of first- to third-degree (occurring in 20-30% of cases), and junctional escape rhythms. Tachyarrhythmias in digoxin toxicity include ventricular ectopy, such as premature ventricular contractions and , as well as more severe forms like bidirectional ventricular tachycardia, which is and occurs in less than 5% of cases. with AV block is another characteristic supraventricular arrhythmia. These proarrhythmic effects can precipitate hemodynamic instability, exacerbating symptoms such as dyspnea and ; bidirectional ventricular tachycardia, in particular, may lead to syncope due to its rapid rate and irregular nature. The presentation of cardiac manifestations differs between acute and chronic toxicity. In acute overdose, ventricular tachycardias are often associated with hyperkalemia, reflecting severe potassium shifts from Na+/K+-ATPase inhibition. Chronic toxicity, typically in patients with renal impairment or drug interactions, more frequently involves AV blocks and bradyarrhythmias. Arrhythmias account for approximately 80% of deaths in digoxin toxicity cases. Recent data indicate a fatality rate of 10-20% in severe cases, with 11.1% mortality at 30 days in a cohort of 658 patients. Non-cardiac symptoms like nausea may precede these cardiac signs, serving as an early warning.

Diagnosis

Laboratory Evaluation

Laboratory evaluation plays a crucial role in confirming toxicity, assessing its severity, and guiding management, with serum concentration serving as the primary . The therapeutic range for serum is typically 0.8 to 2.0 ng/mL (with lower targets of 0.5–1.0 ng/mL recommended for per 2022 AHA/ACC/HFSA guidelines), while levels exceeding 2.4 ng/mL are considered toxic, and concentrations above 10 ng/mL in acute overdose indicate life-threatening toxicity. Accurate measurement requires sampling at least 6 hours after the last dose to allow for post-distribution equilibration, as earlier levels may reflect absorption rather than steady-state concentrations. Electrolyte disturbances, particularly , are hallmark findings in digoxin toxicity due to inhibition of the sodium- pump. In , serum levels greater than 5.0 mEq/L are common and serve as a prognostic indicator, with concentrations above 5.5 mEq/L associated with mortality exceeding 50%. Routine monitoring of magnesium and calcium is also essential, as hypomagnesemia or hypercalcemia can exacerbate toxicity. Renal function tests, including blood urea nitrogen (BUN), serum creatinine, and estimated glomerular filtration rate (eGFR), are vital for evaluating digoxin clearance, as the drug is primarily excreted by the kidneys. Impaired renal function often contributes to toxicity accumulation and informs dosing adjustments in chronic therapy. Additional laboratory assessments may include troponin levels if myocardial ischemia is suspected and a complete blood count (CBC) to detect dehydration or anemia, which can worsen toxicity. However, serum levels correlate poorly with clinical symptoms in chronic toxicity, where manifestations can occur even within therapeutic ranges, emphasizing the need for integrated clinical correlation.

Electrocardiographic Findings

Electrocardiographic findings in toxicity range from nonspecific changes to highly specific arrhythmias that aid in bedside , though no single pattern is except in severe cases. The classic "digitalis effect," observed in patients on therapeutic , includes scooped or downsloping ST-segment depression, a shortened , and flattened or inverted T waves; these changes reflect altered but are not diagnostic of toxicity alone and may persist without clinical toxicity. In , the scooped ST appearance is prominent in leads with tall R waves, while prolonged PR intervals and AV dissociation may indicate emerging conduction abnormalities. Unlike Wolff-Parkinson-White syndrome, digoxin toxicity lacks delta waves, helping differentiate supraventricular tachycardias with aberrancy. Toxicity-specific arrhythmias often involve increased automaticity and impaired conduction, manifesting as junctional tachycardia, accelerated junctional or ventricular rhythms, and paroxysmal atrial tachycardia (PAT) with block, where atrial rates exceed 150 bpm but ventricular response is slowed by high-degree AV block (e.g., 2:1 or 4:1 conduction). A hallmark finding is bidirectional ventricular tachycardia (VT), characterized by broad QRS complexes alternating in axis by approximately 180 degrees beat-to-beat, reflecting alternating ventricular activation and considered nearly pathognomonic for severe digoxin toxicity. In acute overdose, severe may widen the beyond 120 ms, exacerbating conduction delays and predisposing to ventricular arrhythmias; serum potassium levels thus influence these patterns, with paradoxically worsening toxicity in chronic settings. For , ECG abnormalities are more sensitive than serum levels, which may not correlate well with clinical manifestations due to factors like timing and tissue binding; serial ECGs are essential to track evolving rhythms and response to , such as resolution of arrhythmias post-antidote administration.

Differential Diagnosis

The differential diagnosis of digoxin toxicity is broad due to its nonspecific gastrointestinal, neurological, and cardiac manifestations, which overlap with numerous acute and chronic conditions, necessitating a systematic approach to exclude mimics and confirm exposure. Cardiac conditions that mimic digoxin toxicity include , characterized by elevation and ischemic ECG changes; electrolyte disorders such as , often secondary to or renal impairment; and beta-blocker overdose, which presents with and . Gastrointestinal and neurological mimics encompass , featuring fever and confusion; , with nausea and in the setting of renal failure; and cerebrovascular accident, manifesting as visual disturbances and . Drug-related causes include toxicity from other antiarrhythmics, such as quinidine, which interacts with to elevate its serum levels and exacerbate arrhythmias; and toxicity, leading to and . Additionally, or coma should be considered, as it can produce , altered mental status, and imbalances resembling effects. Key differentiators include a history of digoxin use or exposure to cardiac glycoside-containing , along with elevated serum levels greater than 2.0 ng/mL, though levels alone do not rule out toxicity in chronic cases. Characteristic ECG findings, such as bidirectional or scooped ST segments, may support suspicion but require correlation with clinical context. The diagnostic approach involves screening to detect or analogs, serum and renal function assessment, and targeted imaging (e.g., head CT for suspected CVA) when indicated; the 2024 expert consensus underscores the importance of contextual evaluation in ambiguous presentations to avoid misdiagnosis.

Treatment

Initial Management

The initial management of digoxin toxicity focuses on stabilizing the patient through supportive care and gastrointestinal decontamination while addressing key imbalances. Immediate assessment and support of airway, , and circulation (ABCs) are paramount, including administration of supplemental oxygen if is present, establishment of intravenous (IV) access, and continuous cardiac monitoring to detect arrhythmias. Hypotension should be treated with cautious IV fluid boluses, typically 250-500 mL of isotonic crystalloid, while avoiding fluid overload in patients with underlying ; bedside can guide volume status assessment. Gastrointestinal decontamination is recommended for acute ingestions to reduce absorption. Activated charcoal at a dose of 1 g/kg orally should be administered if the patient presents within 1-2 hours of , or up to 6-8 hours in select cases, particularly for large overdoses; multiple-dose activated charcoal (0.5 g/kg every 4-6 hours) may be used for sustained-release formulations to interrupt enterohepatic recirculation. is rarely indicated due to the risk of vagal stimulation exacerbating , and emetics or cathartics are contraindicated owing to aspiration risk and potential for worsening electrolyte disturbances. Electrolyte correction is critical, as imbalances exacerbate toxicity. should be promptly corrected with IV (10-20 mEq/hour, guided by serial levels) to a target of 4-5 mEq/L to minimize binding to Na+/K+-ATPase, while avoiding overcorrection that could lead to rebound ; supplementation is withheld if (>5.5 mEq/L) is present unless -specific is available. Hypomagnesemia, common in chronic cases, warrants IV (1-2 g over 10-20 minutes, repeatable if needed) to stabilize cardiac membranes, especially in the setting of ventricular arrhythmias. Hypercalcemia, if present, requires cautious management with fluids and monitoring, but IV calcium is generally avoided, as it may not provide benefit and specific therapies are preferred, though evidence does not support increased mortality risk. General measures include immediate discontinuation of and any interacting medications, with frequent vital sign monitoring every 15-30 minutes in the acute phase and serial electrocardiograms to track rhythm changes. Patients with severe —manifested by hemodynamic instability, life-threatening arrhythmias, or >5.5 mEq/L—should be admitted to an for close observation, per current guidelines. In severe cases, preparation for specific may be necessary alongside these supportive steps.

Specific Antidote Therapy

(DigiFab) serves as the definitive for reversing toxicity by neutralizing the circulating free . This ovine-derived fragment binds with high affinity (10⁹ to 10¹⁰ M⁻¹), forming an inert complex that prevents interaction with the Na⁺/K⁺-ATPase pump, thereby restoring normal cardiac and systemic function; the complex is primarily excreted via the kidneys. Indications for digoxin immune Fab therapy encompass life-threatening arrhythmias, such as severe ventricular arrhythmias or second- and third-degree , with serum potassium exceeding 5.5 mEq/L in adults (or ≥6 mEq/L per 2024 expert consensus without alternative causes), acute ingestions with serum levels greater than 10 ng/mL, and chronic toxicity with levels above 6 ng/mL accompanied by end-organ dysfunction or severe symptoms. The 2024 Expert Consensus on Digoxin Toxicity provides strong endorsement for these criteria and expands to include refractory unresponsive to atropine or other supportive measures, emphasizing its role in reducing mortality risk in severe cases. Dosing of digoxin immune Fab is tailored to the estimated digoxin body burden and administered intravenously as a lyophilized powder reconstituted to 10 mg/mL. For chronic toxicity with a known serum level, the number of 40 mg vials required is calculated as (serum digoxin concentration in ng/mL × patient weight in kg) / 100; for acute ingestion of a known amount, vials = (ingested digoxin in mg × 0.8) / 0.5 mg per vial. In scenarios of unknown ingestion or when rapid intervention is needed, an empirical dose of 10 vials for adults (or 5 vials for children) is infused over at least 30 minutes, with faster administration reserved for cardiac arrest. Clinical response to typically begins within 20 to 60 minutes, with 50% to 90% of patients showing improvement in arrhythmias or hemodynamic stability, and full reversal often achieved in 4 to 6 hours as free levels become undetectable. However, rebound elevation of free occurs in 10% to 20% of cases, particularly with renal impairment or large ingestions, necessitating hourly monitoring of serum potassium, electrocardiogram, unbound levels (if available), and for up to 4 to 6 hours post-infusion, with extended cardiac observation potentially required for several days. Adverse effects of digoxin immune Fab are generally uncommon but include hypokalemia in approximately 13% of patients due to intracellular potassium shifts following toxicity reversal, which mandates close electrolyte monitoring and supplementation as needed. Allergic reactions, including rare anaphylaxis (<1% incidence), may occur due to ovine protein sensitization, especially in those with prior exposure; other reactions encompass exacerbation of congestive heart failure (13%) or atrial fibrillation (7%). Each 40 mg vial costs approximately $5,000, contributing to high treatment expenses in severe cases.

Arrhythmia Management

Management of arrhythmias in digoxin toxicity requires targeted interventions to address rhythm disturbances while considering the underlying mechanism of increased vagal tone and automaticity. Digoxin-specific antibody fragments (DSFab) serve as the first-line therapy for severe cases, rapidly reversing toxicity and stabilizing rhythms. For bradyarrhythmias, often vagally mediated, atropine is administered intravenously at 0.5-1 mg every 3-5 minutes, up to a total dose of 3 mg, to block vagal effects and improve heart rate. If refractory to atropine, temporary transvenous pacing may be employed, though it should be avoided in the presence of hyperkalemia due to the risk of exacerbating conduction abnormalities. Ventricular tachyarrhythmias, such as (VT), are managed with lidocaine as the preferred agent, given at an initial dose of 1-1.5 mg/kg intravenously, followed by additional boluses of 0.5-0.75 mg/kg if needed, up to a total of 3 mg/kg; this is favored over , which may worsen atrioventricular conduction. (DC) cardioversion is reserved as a last resort owing to the high risk of precipitating or . Special considerations include avoiding calcium administration in , as it may not provide benefit and specific therapies are preferred, though evidence does not support increased mortality risk. serves as an alternative for digoxin-induced VT, loaded at 15-20 mg/kg intravenously at a rate of 50 mg/min, to enhance atrioventricular conduction without exacerbating . Continuous electrocardiographic (ECG) monitoring is essential to detect and respond to evolving . Recent 2025 guidelines emphasize intravenous for torsades de pointes-like rhythms in toxicity, particularly when associated with ventricular arrhythmias, at a dose of 1-2 g over 5-60 minutes. With combined therapy including DSFab and antiarrhythmic agents, approximately 80% of digoxin-induced arrhythmias resolve, though beta-agonists and agents that enhance digoxin effects should be avoided to prevent precipitation of .

Prevention and Prognosis

Preventive Strategies

Preventive strategies for digoxin toxicity emphasize proactive monitoring, careful dosing, and patient-centered interventions to mitigate risks, particularly in vulnerable populations such as the elderly or those with renal impairment. Routine monitoring of serum digoxin levels is essential, typically checked one week after initiation to confirm and then at regular intervals, such as every 3 to 6 months, with increased frequency in the elderly or those with renal impairment to ensure levels remain within the therapeutic range of 0.5 to 0.9 ng/mL. Renal function, assessed via estimated (eGFR), should be evaluated every 6 to 12 months or more often if changes occur, as digoxin is primarily renally cleared; doses should be reduced to 0.125 mg daily or every other day if eGFR is below 50 mL/min/1.73 m² to prevent accumulation and toxicity. Screening for drug interactions is critical, as (P-gp) inhibitors like verapamil can increase plasma concentrations by 60% to 90%, raising risk; co-administration should be avoided when possible, or the lowest effective dose used with close level monitoring. plays a key role in prevention, including teaching recognition of early symptoms such as , visual changes, or arrhythmias to prompt timely medical contact, promoting adherence through tools like pill organizers—especially beneficial for elderly patients to reduce dosing errors—and advising avoidance of over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs), which can worsen renal function and elevate levels. According to the 2022 AHA/ACC/HFSA guidelines, levels should be targeted below 1.0 ng/mL in elderly patients or those with to minimize toxicity, with consideration for deprescribing if no clear benefit is observed and safer alternatives like angiotensin receptor-neprilysin inhibitors (ARNIs) are available, particularly in with reduced where ARNIs are first-line. At the institutional level, implementing alerts for high-risk scenarios—such as elevated doses, interacting medications, or missing labs—has been shown to improve safe use, with studies demonstrating effectiveness in addressing issues like or absent levels, potentially reducing toxicity incidence by up to 50% through protocol adherence.

Clinical Outcomes

The prognosis of digoxin toxicity varies based on the type of exposure, severity, and timeliness of intervention, with overall mortality rates ranging from 4.5% at seven days to 11.1% at thirty days in a large cohort of primarily chronic cases. Severe cases, particularly those involving acute overdose, carry a higher mortality risk of approximately 20%, while chronic toxicity in elderly patients with comorbidities tends to have lower rates around 4-5%. Hyperkalemia exceeding 5.5 mEq/L in acute toxicity is a critical prognostic marker, historically associated with near-100% fatality without digoxin-specific antibody fragments (Fab), though modern Fab therapy substantially mitigates this risk. With prompt administration of , recovery is achieved in 80-90% of cases, often with complete reversal of within 30-180 minutes. In , residual arrhythmias or incomplete resolution may occur in some patients due to underlying comorbidities, necessitating ongoing monitoring. Long-term implications include an elevated risk of hospitalization following episodes, with hazard ratios around 1.5-1.6 associated with ongoing or prior exposure in patients. Among survivors, is frequently deprescribed, with guidelines recommending against restarting maintenance therapy in most cases requiring Fab, occurring in up to 50% or more of such patients to prevent recurrence. Key factors influencing outcomes include early Fab use, which reduces mortality in life-threatening toxicity and may shorten stays by limiting toxicity duration. Adherence to recent consensus guidelines, including the expert recommendations on and , correlates with improved survival and fewer adverse events, as reflected in declining digoxin-related hospitalizations through 2025 monitoring updates. Complications in severe often involve renal failure due to hemodynamic instability and reduced clearance, exacerbating the cycle of accumulation.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK459165/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10599802/
  3. https://www.ahajournals.org/doi/10.1161/circheartfailure.113.000784
  4. https://emedicine.medscape.com/article/154336-overview
  5. https://www.ccjm.org/content/91/8/489
  6. https://www.ajconline.org/article/S0002-9149(22)00836-0/fulltext
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC4816869/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC11033962/
  9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020405s013lbl.pdf
  10. https://www.ncbi.nlm.nih.gov/books/NBK556025/
  11. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
  12. https://pubmed.ncbi.nlm.nih.gov/25089630/
  13. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020405s006lbl.pdf
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC5778102/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC5399982/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC4546820/
  17. https://pubmed.ncbi.nlm.nih.gov/8492339/
  18. https://revistaemergencias.org/wp-content/uploads/2023/09/Emergencias-2019_31_1_39-42-42_eng.pdf
  19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019152s044lbl.pdf
  20. https://www.ahajournals.org/doi/10.1161/CIRCEP.121.007955
  21. https://www.amjmed.com/article/S0002-9343(24)00543-6/fulltext
  22. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/009330s031lbl.pdf
  23. https://emcrit.org/ibcc/dig/
  24. https://emedicine.medscape.com/article/2089975-overview
  25. https://www.medsafe.govt.nz/profs/PUArticles/March2023/Digoxin-toxicity-don%27t-break-my-heart.html
  26. https://pubmed.ncbi.nlm.nih.gov/1997015/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC8956470/
  28. https://emedicine.medscape.com/article/154336-clinical
  29. https://www.uspharmacist.com/article/digoxin-toxicity-a-review
  30. https://digifab.health/en-us/digoxin-toxicity/risk-factors.html
  31. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020405s005lbl.pdf
  32. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/628600
  33. https://eyewiki.org/Color_Vision
  34. https://iovs.arvojournals.org/article.aspx?articleid=2190103
  35. https://www.sciencedirect.com/science/article/pii/S0735675724002055
  36. https://www.uptodate.com/contents/digitalis-cardiac-glycoside-poisoning
  37. https://litfl.com/digoxin-effect-ecg-library/
  38. https://litfl.com/digoxin-toxicity-ecg-library/
  39. https://litfl.com/bidirectional-ventricular-tachycardia-bvt-ecg-library/
  40. https://pubmed.ncbi.nlm.nih.gov/6751790/
  41. https://pubmed.ncbi.nlm.nih.gov/39265879/
  42. https://emedicine.[medscape](/page/Medscape).com/article/154336-treatment
  43. https://emedicine.medscape.com/article/154336-treatment
  44. https://www.ncbi.nlm.nih.gov/books/NBK482294/
  45. https://pubmed.ncbi.nlm.nih.gov/19201134/
  46. https://www.ncbi.nlm.nih.gov/books/NBK556101/
  47. https://www.fda.gov/media/74693/download
  48. https://buyandbill.com/digifab-j1162/
  49. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.105.166558
  50. https://www.drugs.com/dosage/lidocaine.html
  51. https://wikem.org/wiki/Digoxin_toxicity
  52. https://www.anzcor.org/home/adult-advanced-life-support/guideline-11-5-medications-in-adult-cardiac-arrest
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC9588603/
  54. https://www.sps.nhs.uk/monitorings/digoxin-monitoring/
  55. https://pubmed.ncbi.nlm.nih.gov/10527640/
  56. https://pharmaceutical-journal.com/article/ld/digoxin-monitoring-and-toxicity-management
  57. https://www.singlecare.com/blog/digoxin-interactions/
  58. https://www.ncbi.nlm.nih.gov/books/NBK2670/
  59. https://academic.oup.com/jamia/article/11/4/270/974562
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC6120286/
  61. https://www.ahajournals.org/doi/10.1161/circep.114.002292
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC12261267/
Add your contribution
Related Hubs
User Avatar
No comments yet.